Two human chromosomal regions, the HLA region on chromosome 6p2 1 and the insulin gene region on chromosome llp15, have been investigated in detail for more than 10 years for the presence of IDDM susceptibility genes. Recent genome searches indicate the possible existence of many additional susceptibility genes in IDDM. The lengthy and protracted studies to prove the linkage and identity of the susceptibility genes in the HLA and insulin gene regions provide a perspective and background for understanding the complexities and time course for characterization of the putative additional IDDM susceptibility genes uncovered by genome searches. Diabetes 45:544-551, 1996
THE HLA REGION
The major histocompatibility complex (MHC), or HLA (human leukocyte antigen) region in humans, is a segment of -3,500 kb on the short arm of chromosome 6. It contains rrlany genes, some of which are shown in Fig. 1 . Many of these genes are concerned with the function and regulation of the immune response. Class I genes consist of HLA-A, -B, and -C, while class I1 genes are divided into the main subregions, DR, DQ, and DP. The LMP (low molecularweight protein) genes and the TAP (transporters associated with antigen processing) genes are both involved in antigen processing. The class 111 region genes encode products with a variety of functions, including complement components (C4A, C4B, C2, and Bf), tumor necrosis factors (TNF-a and -P), and the 21-hydroxylase genes (CYP21P and CYP21).
Association studies of markers with IDDM susceptibility. The genes of the HLA region on chromosome 6p21 and their encoded proteins have a high degree of polymorphism. These polymorphisms are not randomly distributed in the general population and thus show linkage disequilibrium, i.e., the distributions of polymorphisms at different loci do not reach equilibrium in the population, and thus they have preferential associations with each other. These frequency distributions can be determined and compared in control and test populations. Linkage disequilibrium thus allows associations of a marker locus to a disease locus (reflected by the phenotype) even if the marker locus itself is not actually involved in the disease. Thus, in studies comparing disease and control populations (case-control studies), significant differences in polymorphic marker frequencies (alleles) between the two populations suggest that the chromosomal region defined by the marker is involved in the disease.
The association of the HLA region with IDDM susceptibility was first reported in case-control studies during 1973 and 1974 (16, 17) . In a study of unrelated diabetic patients, the HLA class I alleles B15, B8, and B18 were increased in frequency, while the frequency of B7 was decreased as compared with a nondiabetic control population. The first family studies demonstrating linkage between HLA class I alleles and IDDM were reported in 1975 and 1976 (18, 19) .
Subsequent serological typing for class I1 HLA loci made it clear that a stronger positive association of IDDM was seen with DR3 and DR4 than with the class I HLA-B alleles or with the class I11 region markers (20, 21) . The further development and application of DNA typing for class I1 HLA markers made it possible to more specifically examine the class I1 HLA associations with IDDM susceptibility. For example, DQBl addition, early treatment of NOD niice with anti-class I1 monoclonal antibodies also prevents the development of diabetes (38) . These results are consistent with a role of both HLA-DR and HLA-DQ in human IDDM.
It is currently unknown how the HLA class I1 genes Class 11
influence the pathogenesis of IDDM. The class 11 susceptibilu 45$ky 0 0 0 0 0 0 ity molecules could promote an autoimmune reaction either because they bind the antigenic islet-cell fragment with a particularly high affinity (39) or, alternatively, because they bind too weakly, resulting in lack of or abnormal tolerance
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with IDDM cannot be adequately tested or understood at present. 
THE INSULIN GENE REGION
was subdivided into DQ3.1 (DQ7) and DQ3.2 (DQ8), the former being negatively and the latter positively associated with susceptibility to IDDM (22) (23) (24) . Fur-thermore, DRBl was subdivided into subtypes (Dw4, DwlO, Dw13, Dw14, and Dw15), with only Dw4 and DwlO showing positive association with the disease susceptibility (25) . Indeed, the absolute risk for 1DDhl is 1 in 15 for individuals who are DR3/Dw4-DwlO,D&3.2 compared to just 1 in 42 for individuals who are DR3/DR4 (25) . Although the primary susceptibility to IDDM clearly resides in the HLA class I1 region, the actual susceptibility determinants are still undefined. Biological role of the HLA class I1 region. Sequence comparisons of DQB1 alleles reveal a correlation between amino acid position 57 (non-Asp") of the DQ P-chain (26) (27) and susceptibility to IDDM. For example, disease-associated haplotypes containing HLA-DR3 and HLA-DR4 have Ala" and neutralfweakly positive haplotypes such as HLA-DR1 have ~e r~~, while protective haplotypes containing HLA-DR2 have Asp57. Amino acid polymorphism at posltion 57 could affect the interaction between the class I1 molecule, the peptide antigen, and the T-cell receptor and thus control the specificity of the immune response to foreign and/or self-antigens. However, other residues in the DQ (3-chain appear to be involved (28, 29) , as well as the DQ a-chain (30 -33).
Several lines of evidence indicate that the class I1 molecules themselves may be involved in the pathogenesis of diabetes. In the transgenic NOD mouse, the expression of I-A@ (mouse class I1 DQB equivalent) transgenes carrying Asp57 instead of the nornial ~e r~~ prevents diabetes (34, 35) . Likewise, expression of Pro56 instead of the normal HissG prevents diabetes (36) . Furthermore, the expression of I-E transgenes (mouse HLA-DR equivalents that are absent in NOD niice) confers resistance to the disease (36, 37) . In (45) . The human insulin gene was cloned (46,47) and mapped to chromosome 11 (48) in 1980. The first association studies with diabetes susceptibility, involving IDDM and NIDDM (49) (50) (51) , and abnormal glucose regulation (53) were inconclusive, probably because of the relatively sn~all populations analyzed. However, in larger studies, homozygosity for class 1 alleles (smaller alleles defined by restriction fragment length polymorphism [RFLP]) was increased in frequency in unrelated IDDM populations as compared with control populations (4, 5) . Conclusive evidence of linkage of the insulin gene region to IDDM was not reported until 1991 and 1992 (6,7). The difficulty in determining linkage of this region to IDDM susceptibility resulted from the high frequency of class I (disease-associated) alleles in the general population. However, when family studies in which affected offspring from parents who were heterozygous for class I and class 111 alleles (the latter are non-disease-associated alleles in case-control studies) were analyzed, linkage was clearly indicated (6,'i) . Association of the variable number of tandem repeats (VNTR) region flanking the insulin gene with diabetes susceptibility. The polymorphism studies of the INS locus showed the molecular heterogeneity to be due to VNTR sequences flanking and located only 365 bp from the transcriptional initiation site of the insulin gene (53-56). The sequences are tandem repeats of 14-to 15-bp elements composed of the consensus sequence ACAGGGGTGTGGGG ( Table 1) . The sequenced alleles range in size from 27 to 150 repeat elements ( Table 2 ). The first class I (two diabetesassociated alleles each containing either 34 or 45 repeat VNTR  INS TABLE 1 Sequence of various repeat elements present in VNTR regions (56), respectively. Table 2 presents the sequences of these VNTR alleles as well as nine hitherto unpublished sequences from our laboratory. The class I VNTR allele (XHI-1) Inay have been derived from an ancestral class I11 VNTR allele, since its sequence is identical at the 5' and 3' ends of the class 111-G VNTR allele and quite different from the other class I VNTR alleles (Table 2 ). Detailed analysis of the INS region indicates the presence of a number of other polymorphisms (n = 11; Fig. 2 ) outside of the VNTR region that are in strong linkage disequilibrium with the VNTR and thus associated with IDDM susceptibility (6, 7, (57) (58) (59) (60) . Analysis of the presence of these polynlorphisms in different populations and on different diabetes-associated and non-diabetes-associated haplotypes indicates that the linkage of these polymorphisms is secondary to the primary association of the VNTR with IDDM susceptibility (57) (58) (59) (60) .
In addition to the variations in numbers of repeat elements, there are variations in element sequences and in the presence and location of individual elements within each class of alleles (Tables 1 and 2 ). At this time, it is not known which aspect of these variations (repeat number, element sequence, element number, or location within each VNTR allele) relates to disease susceptibility. For instance, recent studies suggest that not all class 111 (58,601 or class 1 (59) VNTR alleles are equally associated with the disease susceptibility. Specifically, some class I11 VNTR alleles appear to be strongly protective for IDDM susceptibility, while others are weakly protective or neutral (58, 60) . In addition, the 698-VNTR class I subtype described by Bennett et al. (59) is reported to be negatively associated with disease susceptibility, in contrast to other class I VNTR alleles (59) . The 698 allele is identical in size to the XHI-1 allele (Table 2) , and it has been reported not to be associated with IDDM, as are other class I VNTR alleles (59) . The frequency of repeat element e (ATAGGGGTGTGGGG) in this allele (Table 2) may correlate with the degree of disease protection (58, 59) , but further population and gene expression studies are required to confirm a role for this repeat element in the specific effects of the AHI-1 VNTR allele. Biological role of the VNTR region. Recent studies indicate the VNTR region has a biological role in modulating gene expression (59, 61, 62) . However, the exact role is presently unknown because of conflicting reports as to whether the class I VNTR alleles cause lesser (61) or greater (59, 62) gene expression. In two reports (59, 62) , it was claimed that class I-associated insulin gene expression is elevated as compared with class I11 insulin gene expression. In contrast, Kennedy et al. (61) reported that class 111 VNTR reporter gene constructs had three times higher reporter gene expression than class I VNTR. However, in our own studies (Table  3) , our results do not support those of Kennedy et al. (61), since we find three times higher levels of class I-driven reporter gene expression compared with those of class 111. It remains to be determined if methodological differences can account for some of these discrepancies, e.g., design of plasmid constructs, method of DNA transfection, differences in the cell lines used for transfections, etc. Regardless of the direction of the VNTR effect on gene expression, it remains to be seen how the variant gene expression is related to IDDM susceptibility, e.g., abnormal insulin or IGF-I1 gene expression.
THE SEARCH FOR NEW SUSCEPTIBILITY LOCI
Genome searches are only a preliminary step in identifying and characterizing a susceptibility Incus. For example, recent reports (9, j d a a l a a a a a c b a a a a d a a b a a a d a a a d a d a a b a a a a d a b a d (63) suggested a statistical level of P = 0.001 for establishing presumptive evidence of linkage in genome searches, to be followed by replication of the results in a totally independent population to prove linkage. However, Lander and Kruglyak (64) propose the more stringent criteria of an MLS of 2.2 to provide suggestive linkage (P < 7 X and an MLS of 3.6 (P < 2 x to obtain significant linkage. Even with an MLS of 3.6, a false~positive rate of 5% will occur in genome searches (64) . These authors further suggest that replication studies are necessary but should be reserved for cases in which significant linkage has already been obtained in an initial study or combination of studies. In replication studies (in a totally new Set of families), a nominal Pvalue of 0.01 would be required to confirm linkage, since only a single candidate marker is being tested. Table 4 shows the results of several genome searches for IDDM susceptibility loci. By the criteria of Lander and Kruglyak (64) , none of the searches provide evidence of significant linkage in individual studies, although several show evidence of suggestive linkage. Since most of the studies have overlapping families in common (many obtained from the British Diabetes Association [BDA] and Human Biological Data Interchange [HBDI] repositories), it is not currently possible to pool data from the separate studies. However, for IDDM8 (marker D6S264), the British (9) (MLS = 1.4) and American (12) (MLS = 2.0) families are from independent populations and the combined data provide an MLS of 3.4, which approaches but does not quite reach the significant linkage threshold proposed by Lander and Kruglyak (64) .
Disease heterogeneity and interaction of susceptibility loci. In addition to the unknown but substantial degree of overlap in the study populations shown in Table 4 , detennination of linkage is further complicated by the wide range of selection criteria used for inclusion of families in the various genome searches. For example, the age of onset of diabetes in the affected sibling pairs (ASPs) is restricted in some studies to those diagnosed before the age of 18 years (13), while in other studies the families are comprised of affected subjects with age of onset up to 45 years of age (10) whose clinical form of diabetes is unclear. In some studies, families with diabetic parents were also included, which would alter the expected ASP sharing frequencies and make detection of linkage more difficult.
Further complicating the study of linkage in poIygenic diseases is the question of interaction of the various disease susceptibility loci. Table 4 The consideration of gene interaction in polygenic diseases during genome searches introduces an additional layer of difficulty in determining the significance of LOD scores. We believe the best method to assess the chance of falsepositive findings in polygenic diseases will be the use of simulation methodologies. This technique creates tens of thousands of simulations of a population of ASP families in whom the distribution of the markers under consideration is completely randomized. Differences between the test and simulated populations can thus be compared and empirical P values experimentally determined. Using simulation testing, thus an artificial and arbitrary correction factor for multiple methods of grouping the ASPs would not be needed, especially when the various ASP groupings are not independent.
We recently described such a simulation package for ASP analyses in polygenic diseases called Computerized Affected Sibling Pair Analyzer and Reporter (CASPAR) (65) . CASPAR was implemented to automate ASP analyses using multiple loci simultaneously and assesses the statistical significance of the LOD scores obtained by simulation methods. Results using CASPAR indicate that linkage for IDDM5 in HLA-DR3 ASPs is significant at the P = 0.001 level, while the IDDMV IDDMl and IDDM7LDDM2 linkage results are both significant at the P = 0.002 level (D.O., K.H.G., unpublished observations).
Together, the studies in Table 4 provide strong evidence to suggest linkage of a number of new markers with IDDM susceptibility. However, additional experiments will be required to prove linkage and decipher specific interactions between the loci. For instance, it is not clear whether the chromosome 6q24-27 region contains two separate susceptibility loci, IDDM5 and I W 8 , and whether the 2q31 region contains more than one susceptibility gene (12-14). There is a dire need to study a greater number of families, and in addition, it would be very valuable to have a common and standardized database to realize the maximum amount of information from the families currently typed.
Even with larger numbers of families and maximum data extraction, evidence of linkage derived from ASP sharing frequencies may remain weak for some suggestive IDDM loci, and other methods may be needed to prove linkage. These weaker susceptibility loci may in fact be real, and suggestive linkages should therefore continue to be actively pursued. IntrafamiLial association studies. One method for establishing linkage of a weakly contributing susceptibility locus uses intrafamilial association of specific markers. Indeed, family-based association studies were used to prove linkage of IDDM2 when the standard ASP linkage analyses failed to provide strong evidence (6,7). The family-based association study uses a transmission disequilibrium test (TDT), which is based on the transmission of the associated marker allele from a heterozygous parent to an affected offspring (66) . This test has the advantage that it does not require data on multiple affected family members or on unaffected siblings. However, TDT has the disadvantage that it can only detect linkage between the marker locus and the disease locus if linkage disequilibrium (0-2 cM) is present. The TDT test has been used to provide additional support for linkage of IDDM7 (14) and GCK (the glucokinase gene) (15) with IDDM susceptibility (Table 4) . These studies remain to be confirmed in additional families and with additional marker polymorphisms. Identification and characterization of susceptibility genes. Both IDDM1 and IDDM2 were identified and characterized using the candidate gene approach. It is possible that other genes involved in the immune response, glucose metabolism, or P-cell function, e.g., cell surface antigens, glucagon, receptors, etc., will be tested and found to be associated with IDDM. However, to systematically find new susceptibility genes, positional cloning (67,68) must be used in chromosomal regions implicated in diabetes susceptibility through genome searches. Although positional cloning has never been previously used in a polygenic disease, IDDM may provide a good model system to test this approach using the strategy proposed below.
Once linkage of a chromosomal region to diabetes susceptibility is proven, the actual susceptibility gene must then be located. Even large linkage studies using 500 ASPs can only narrow down the disease susceptibility region to 10-20 cM. At this stage, fine mapping of the new susceptibility genes will be required using linkage disequilibrium methods in case-control and intrafamilial association studies. Linkage disequilibrium is usually seen when polymorphisms are separated by 0-2 cM. For example, linkage disequilibrium of the markers in the HLA region extends for at least 2 cM, while linkage disequilibrium in the insulin gene region is strong only over an area of 5-10 kb. Dinucleotide repeats (69) can be used in linkage disequilibrium testing (14,15), and these are at a sufficient density in most regions of the genome to provide a marker every 1-2 cM (70, 71) . In specific chromosomal regions where additional DNA polymorphisms are required, yeast artificial chromosomes and cosmid clones can be used to generate additional markers. In fact, physical maps and contiguous yeast artificial chromosomes containing -1 million base pairs each have recently become available, with the prospect of mapped cosmid contigs (-50,000 bp) to follow soon (72). Rapid advances are also being made in mutation (polymorphism) detection with the use of fluorescent-based polymerase chain reactionsingle-strand conformation polymorphism (PCR-SSCP) analysis (73) and improved enzymatic cleavage methods (74, 75) , which will result in improved and detailed polymorphism maps of specific chromosomal regions. Once DNA polymorphisms are identified that are in linkage disequilibrium with the disease susceptibility, the full gamut of studies described above for HLA and insulin can be put into play. These include determining which DNA polymorphism provide the highest population risk for the disease, whether the polyrnorphisms are associated with disease in other racial groups, and what biological role the gene and its mutations play.
CONCLUDING REMARKS
It has been known for quite some time that IDDM is one of a group of autoimmune diseases that have in common an association with specific HLA alleles. In fact, there are many families that are aWicted with other autoimmune diseases in addition to IDDM, e.g., lupus erythematosis (connective tissue, HLA-Dm), rheumatoid arthritis (joints, HLA-DR4), membranous glomedonephritis (kidney, HLA-DM), and celiac disease (intestine, HLA-DR3), although the diseases are not necessarily shared in the same affected subjects (76-79). The unknown basis for specific target organ response (e.g., gut or p-cells) in these autoimmune diseases is clearly a key to the understanding and ultimate prevention and cure of the specific disease. It is likely that organ-specific non-MHC genes determine the basis for organ specificity. In the case of IDDM, identification of the VNTR complex of the insulin gene may be the first instance in which an organspecific region has been identified that may spell out the ultimate target address. It is likely that other P-cell-specific genes will be defined that affect IDDM susceptibility, e.g., genes coding for transcription factors andlor those affecting p-cell maintenance or replication.
Our expanding knowledge of the factors affecting p-cell replication and control of insulin gene expression will likely lead to the identification of different pathways for the pathogenesis of IDDM. Potential evidence of different puta-tive constellations of susceptibility gene interactions (see above) suggest that there may indeed be heterogeneity in the pathogenetic mechanisms underlying IDDM. The biological mechanisms of interaction between the MHC genes dictating the immune response and the targeting genes are, of course, completely unknown at this time.
Note that there may be some genes in common between some forms of NIDDM and IDDM, since a majority (-85% in our exper~ence) of IDDM patients give a family history of adult-onset diabetes. Finally, even the hypothesized environmental factors that are thought to contribute to the onset of IDDM may themselves be in part genetically determined. For all these reasons, there is thus a need to do thorough and structured genome searches for all the potential contributors to diabetes susceptibility.
Genome searches are only an initial stage in characterizing new susceptibility genes. First, linkage must be proven, which is not a small task. Indeed, thousands of ASP families may be required to prove linkage and to decipher interactions of some of the IDDM susceptibility genes. Many of the susceptib~lity genes and their reported putative interactions at this time may in fact turn out to be false-positives. It is also likely that other IDDM susceptibility genes that were missed in genome searches will be found by candidate gene approaches. To identify the actual susceptibility loci presented in the genome searches, DNA polymorphisms must next be associated with the disease in case-contra1 and intrafamilial studies. Studies of marker alleles from HLA and INS casecontrol and familiaI association studies suggest a minimum and rnaximum distance between the marker polymorphism and the actual susceptibility locus, which will be necessary for success in identify~ng additional susceptibility loci: -5 kb (INS) to -2,000 kb (HLA).
For at least some linked genes, large-scale cloning and polymorphism detection analysis will be required before detection of the initial associations. In initial candidate studies of the INS associations, investigators expected a possible association with NIDDM and were surprised that the stronger association was with IDDM. These considerations suggest that one should not be too stringent in assuming what role the candidate gene should have, and therefore, all known genes and marker alleles in the region of linkage should be tested in association studies.
Once t.he initial associat,ion studies are positive for both case-control and intrafamilial studies, results from INS and HLA demonstrate how difficult it is to prove that a specific nucleotide or allelic variation is the primary one in the disease association, particularly if the region af variation was thought to be nonfunctional DNA, as was the case with the VNTR region. Exhaustive studies of all polymorphisms in the region are required on disease-associated and non-diseaseassociated haplotypes, as well as studies in different racial populations. Even with all these studies, it is difficult to rule out the possibility of secondary interactions with closely linked markers on the susceptible haplotype.
Finally, after the strongest associations with a gene are found, it remains essential to show a function for the It is now quite clear that substantial amounts of time and additional resources will be required for the identification and characterization of the next generation of IDDM susceptibility genes and their interactions. However, the groundwork is in place to make this a feasible and eminently worthwhile endeavor. As has happened in past diabetes research (of insulin as a hormone, insulin protein and nucleotide sequencing, insulin crystal structure, etc.), this aspect of diabetes research will inekltably have a major impact on other polygenic diseases as well. Because of the emerging evidence of a heterogeneous pathogenetic etiology for IDDM, it is doubtful that any single therapeutic or preventive approach can be used to prevent or cure diabetes. It thus seems clear that sorting of the genetic basis underlying each pathogenetic form is essential if comprehensive prevention or cure of this disease is to be accomplished.
